Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
|Videos|May 7, 2021
Dr. Alexander Kretschmer explains how the ExoDx Prostate test works
Author(s)Urology Times staff
Advertisement
Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
4
SureCore needle: Interim data show longer, less fragmented cores
5